Virpax Pharmaceuticals ( (VRPX) ) just unveiled an update.
Virpax Pharmaceuticals has been notified by Nasdaq of not meeting the minimum bid price requirement of $1.00 for its common stock over the past 30 business days. The company will remain listed as it seeks to correct the deficiency by April 2, 2025, with the possibility of a 180-day extension. If unsuccessful, Virpax may face delisting but is considering measures such as a reverse stock split to regain compliance.
For an in-depth examination of VRPX stock, go to TipRanks’ Stock Analysis page.
